Invasive fungal infections: Recent epidemiology data and new antifungal agents;Les infections fongiques invasives: Epidemiologie et nouvelles therapeutiques

Presse Medicale

Volumn 29, Issue 37, 2000, Pages 2051-2056

  Granier, F ^a  

^a Svc de Med Interne et Mal infect   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [5 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4, TRIAZOL 1 YL)PROPYLTHIO] 1,3 DIOXAN 2 YL] 1,3 BUTADIENYL] 3 FLUOROBENZONITIRLE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CASPOFUNGINE; CYCLOSPORIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NYSTATIN; OMEPRAZOLE; PHENYTOIN; POSACONAZOLE; PREDNISOLONE; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; SCH B56592; UNCLASSIFIED DRUG; VORICONAZOLE; TRIAZOLE DERIVATIVE;

DISEASE TRANSMISSION; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; EYE TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INFECTION RATE; LIVER TOXICITY; MORTALITY; MYCOSIS; REVIEW; SKIN MANIFESTATION; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; CANDIDIASIS; IMMUNE DEFICIENCY; RISK FACTOR;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; NYSTATIN; RISK FACTORS; TRIAZOLES;

EID: 0034598103     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Epidemiologie des infections nosocomiales fongiques: Evolution et tendances
2. International surveillance of blood stream infections due to Candida species: Frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole and voriconazole among isolates collected from 1997 through 1999 in the United States, Canada, Latin America and Europe
3. Population-based surveillance for Candida bloodstream Infections: Trends in incidence of disease and azole resistance
4. Risk factors for invasive candidiasis in non-neutropenic critically ill patients
5. Candidemia at a terciary-care hospital: A 3 years review
6. Broad-spectrum antibiotic use in a risk factor for breakthrough candidemia
7. Risk factors and prdictors of outcome in cancer patients with breakthrough candidemia
8. Antifungal susceptibility of yeasts responsible for bloodstream infections
9. Utility of diagnostic criteria for invasive aspergillosis: Consistency of diagnosis in a clinical trial
10. Utility of criteria to assess outcome of invasive aspergillosis: Consistency of response assessments in a clinical trial
11. The isolation of Aspergillus fumigatus after heart-tranplantation is highly predictive of invasive aspergillosis
12. Effect of protective air measurements on nosocomial aspergillosis after liver transplantation
13. Pathogenic Aspergillus species recovered from a hospital water system; a three-year prospective study
14. Novel antifungal drugs
15. Low nephrotoxicity in patients receiving amphotericine B lipid complex (ABLC): A pharmacosurveillance study in Spain
16. EORTC-IFCG phase II study on liposomal nystatin in patients with invasive Aspergillus (IA) infections, refractory or intolerant to conventional/lipid AmphoB
17. New azoles
18. In vitro activity of newer antifungal agents against invasive yeast isolates from cancer patients
19. Voriconazole versus liposomal amphotericine B for empirical entifungal therapy of persistently febrile neutropenic patients: A randomized, international, multicenter trial
20. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (Sch 56592) in the treatment of invasive fungal infections refractory to/or intolerant of standard therapy
21. Posaconazole equivalent to fluconazole in the treatment of propharyngeal candidiasis
22. R-120758, a novel triazole antifungal agent: In vivo antifungal activity
23. Multicenter non comparative study to evaluate safety and efficacy of caspofungin (Cas) in adults with inavsive asperrgillosis refractory or intolerant to amphotericine B (AMB), AMB lipid formulations, or azoles
24. Phase II, randomized, open label study of 2 intravenous dosing regimens of vechinocandin in the treatment of esophageal candidiasis